161 related articles for article (PubMed ID: 35393018)
1. Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke.
Schweizer J; Arnold M; König IR; Bicvic A; Westphal LP; Schütz V; Inauen C; Scherrer N; Luft A; Galovic M; Ferreira Atuesta C; Pokorny T; Arnold M; Fischer U; Bonati LH; De Marchis GM; Kahles T; Nedeltchev K; Cereda CW; Kägi G; Bustamante A; Montaner J; Ntaios G; Sagris D; Foerch C; Spanaus K; von Eckardstein A; Katan M
J Am Coll Cardiol; 2022 Apr; 79(14):1369-1381. PubMed ID: 35393018
[TBL] [Abstract][Full Text] [Related]
2. Isolated insular strokes and plasma MR-proANP levels are associated with newly diagnosed atrial fibrillation: a pilot study.
Frontzek K; Fluri F; Siemerkus J; Müller B; Gass A; Christ-Crain M; Katan M
PLoS One; 2014; 9(3):e92421. PubMed ID: 24647802
[TBL] [Abstract][Full Text] [Related]
3. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke.
De Marchis GM; Schneider J; Weck A; Fluri F; Fladt J; Foerch C; Mueller B; Luft A; Christ-Crain M; Arnold M; Katan M
Neurology; 2018 Feb; 90(6):e455-e465. PubMed ID: 29321236
[TBL] [Abstract][Full Text] [Related]
4. Plasma natriuretic peptides and incidence of subtypes of ischemic stroke.
Berntsson J; Zia E; Borné Y; Melander O; Hedblad B; Engström G
Cerebrovasc Dis; 2014; 37(6):444-50. PubMed ID: 25060145
[TBL] [Abstract][Full Text] [Related]
5. Pro-atrial natriuretic peptide and prediction of atrial fibrillation and stroke: The Malmö Preventive Project.
Berntsson J; Smith JG; Nilsson PM; Hedblad B; Melander O; Engström G
Eur J Prev Cardiol; 2017 May; 24(8):788-795. PubMed ID: 28195503
[TBL] [Abstract][Full Text] [Related]
6. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke.
Katan M; Fluri F; Schuetz P; Morgenthaler NG; Zweifel C; Bingisser R; Kappos L; Steck A; Engelter ST; Müller B; Christ-Crain M
J Am Coll Cardiol; 2010 Sep; 56(13):1045-53. PubMed ID: 20846604
[TBL] [Abstract][Full Text] [Related]
7. Midregional pro atrial natriuretic peptide: a novel important biomarker for noise annoyance-induced cardiovascular morbidity and mortality?
Hahad O; Wild PS; Prochaska JH; Schulz A; Lackner KJ; Pfeiffer N; Schmidtmann I; Michal M; Beutel M; Daiber A; Münzel T
Clin Res Cardiol; 2021 Jan; 110(1):29-39. PubMed ID: 32306084
[TBL] [Abstract][Full Text] [Related]
8. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation.
Smith JG; Newton-Cheh C; Almgren P; Struck J; Morgenthaler NG; Bergmann A; Platonov PG; Hedblad B; Engström G; Wang TJ; Melander O
J Am Coll Cardiol; 2010 Nov; 56(21):1712-9. PubMed ID: 21070922
[TBL] [Abstract][Full Text] [Related]
9. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; Dhillon O; Kelly D; Squire IB; Struck J; Quinn P; Morgenthaler NG; Bergmann A; Davies JE; Ng LL
J Am Coll Cardiol; 2008 May; 51(19):1857-64. PubMed ID: 18466800
[TBL] [Abstract][Full Text] [Related]
10. MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI.
Lindberg S; Jensen JS; Pedersen SH; Galatius S; Goetze JP; Mogelvang R
Eur J Prev Cardiol; 2015 Jun; 22(6):693-700. PubMed ID: 24906365
[TBL] [Abstract][Full Text] [Related]
11. The Role of Electrocardiographic Markers for Predicting Atrial Fibrillation in Patients with Acute Ischemic Stroke: Data from the BIOSIGNAL Cohort Study.
Schütz V; Dougoud S; Bracher K; Arnold M; Schweizer J; Nakas C; Westphal LP; Inauen C; Pokorny T; Duru F; Steffel J; Luft A; Spanaus K; Saguner AM; Katan M
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959294
[TBL] [Abstract][Full Text] [Related]
12. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
14. Newly diagnosed atrial fibrillation after acute ischemic stroke and transient ischemic attack: importance of immediate and prolonged continuous cardiac monitoring.
Sposato LA; Klein FR; Jáuregui A; Ferrúa M; Klin P; Zamora R; Riccio PM; Rabinstein A
J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):210-6. PubMed ID: 20727789
[TBL] [Abstract][Full Text] [Related]
15. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A
Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288
[TBL] [Abstract][Full Text] [Related]
16. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
[TBL] [Abstract][Full Text] [Related]
17. Use of risk scores for predicting new atrial fibrillation after ischemic stroke or transient ischemic attack-A systematic review.
Kishore AK; Hossain MJ; Cameron A; Dawson J; Vail A; Smith CJ
Int J Stroke; 2022 Jul; 17(6):608-617. PubMed ID: 34551649
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of midregional pro-A-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years.
Karakas M; Jaensch A; Breitling LP; Brenner H; Koenig W; Rothenbacher D
Clin Chem; 2014 Nov; 60(11):1441-9. PubMed ID: 25139456
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarkers predicting newly detected atrial fibrillation after ischaemic stroke or TIA: A systematic review.
Ward K; Vail A; Cameron A; Katan M; Lip GY; Dawson J; Smith CJ; Kishore AK
Eur Stroke J; 2023 Mar; 8(1):125-131. PubMed ID: 37021168
[TBL] [Abstract][Full Text] [Related]
20. Atrial Fibrillation, thromboembolic risk, and the potential role of the natriuretic peptides, a focus on BNP and NT-proBNP - A narrative review.
Kerr B; Brandon L
Int J Cardiol Heart Vasc; 2022 Dec; 43():101132. PubMed ID: 36246770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
